Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Levetiracetam NDC 63323-400 by Fresenius Kabi Usa, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Structural Formula - lev1d 0003 01

Structural Formula - lev1d 0003 01

Figure 1 - lev1d 0003 02

Figure 1 - lev1d 0003 02

This text shows the percentage of patients who received different doses of levetiracetam - 7.4% were on 1,000mg/day and 37.1% were on an unknown dose (represented by blank space). The majority, 39.6%, were on 3,000mg/day.*

Figure 2 - lev1d 0003 03

Figure 2 - lev1d 0003 03

This appears to be a statistical report showing percentages and dosages of patients in a study related to "Leveiracetam" and "Loveiracetam". The first two percentages are 35.2% and 20.8%, but without any context or additional information, it is not clear what these percentages represent. The third percentage is 6.3%. The dosages being compared are 1,000 mg/day and 2,000 mg/day, and the number of patients in each group (N) is 106 and 105, respectively. The text does not allow for any further elaboration or interpretation of the findings.*

Figure 3 - lev1d 0003 04

Figure 3 - lev1d 0003 04

Not available.*

Figure 4 - lev1d 0003 05

Figure 4 - lev1d 0003 05

This text provides a table with the percentage of patients using Levetiracetam (N=101) with results for three different categories - 2%, 8%, 19.6%, and 44.6%. There is no additional information to provide a more detailed description.*

Figure 5 - lev1d 0003 06

Figure 5 - lev1d 0003 06

This appears to be a table or graph showing the percentages of patients in a study who were treated with either a placebo or a medication called Levetiracetam. However, without additional context or labels it is difficult to understand the full picture of the study or the outcomes.*

Figure 6 - lev1d 0003 07

Figure 6 - lev1d 0003 07

This appears to be a table or percentages without any context, so it's not possible to provide a useful description of the information presented.*

PREMIERProRx Logo - lev1d 0003 08

PREMIERProRx Logo - lev1d 0003 08

PACKAGE LABEL - PRINCIPAL DISPLAY – Levetiracetam 5 mL Tray Label - lev1d 0003 09

PACKAGE LABEL - PRINCIPAL DISPLAY – Levetiracetam 5 mL Tray Label - lev1d 0003 09

This is the product information for Levetiracetam Injection, a sterile medication used for intravenous (IV) use only. It is used for epilepsy and seizures. Each vial contains 500mg of the drug along with other chemicals such as sodium acetate trihydrate, sodium chloride, and acetic acid. The medication should be stored between 20°C and 25°C and any unused portion should be discarded. The container closure does not contain natural rubber latex. This medication is manufactured by Fresenius Kabi and comes in a box containing ten vials of 5 mL each. The package insert should be consulted for dosage guidelines.*

PACKAGE LABEL - PRINCIPAL DISPLAY – Levetiracetam 5 mL Tray Label - lev1d 0003 10

PACKAGE LABEL - PRINCIPAL DISPLAY – Levetiracetam 5 mL Tray Label - lev1d 0003 10

This is a description of a medication in single dose vial form that is sterile and should only be used for intravenous use. It contains Levetiracetam and sodium acetate among other components. The medication must be diluted before use and the storage temperature should be between 20°C to 25°C. The unused portion should be discarded and the container closure does not contain natural rubber latex. The medication is manufactured by Fresenius Kabi in Lake Zurich, IL.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.